📣 Rapid Communication paper out in @JCO_ASCO | #SunRise4 primary findings & biomarkers ✅ pCR 38% w TAR200+Cet ✅ improved RFS w TAR200+Cet vs Cet mono ✅ 80% complete TURBT baseline revealed utDNA positivity ✅ utDNA status at w12 significantly associated with pCR ✅ utDNA

All reunited again under the DNA #GURetreat25 @SanRaffaeleMI @MyUniSR @CMercinelli @vale_tateo @Anto_cigliola @BrigidaMaiorano

A lot of intense discussions ongoing at @SanRaffaeleMI around biomarkers in GU cancers! @IBCG_BladderCA @GTumors @UroDocAsh @SpiessPhilippe

#Retreat25 = 🔥 energy + 🌍 collaboration + 🚀 progress. Research has no boundaries. Thanks @AndreaNecchi and the amazing faculty. 💙 @montypal @neerajaiims @UroDocAsh @shilpaonc @SpiessPhilippe @PGrivasMDPhD @g_procopio @SScagliarini_ @BrigidaMaiorano @CMercinelli @vale_tateo

At @SanRaffaeleMI #GURetreat Grateful for the opportunity to co-lead the session with #SmritiPadodia @TheLancetOncol with an amazing panel @giannatempopatr @brigidam @SScagliarini_ @CMercinelli @vale_tateo Discussed imp issues affecting women with GU cancers, women GU

At @SanRaffaeleMI #GURetreat25 organized by @AndreaNecchi @SpiessPhilippe gives an outstanding overview of his and Andrea's brainchild @GTumors during Covid. What a massive growth & 🌏 outreach the society has achieved with its efforts in education, patient outreach,

Beautiful talk by @DrShariat on progress with ADCs. Very impressive and elegant work by him studying resistance to EV. @SanRaffaeleMI #GURetreat25 @AndreaNecchi

@AndreaNecchi does a phenomenal job highlighting the explosive growth in bladderca treatment & biomarker landscape with cDNA He is a trailblazer leading the way with next gen IITs @SanRaffaeleMI #GURetreat25 @BrigidaMaiorano

Honored to be at the FOURTH @SanRaffaeleMI #UrologicOncology Retreat, hosted by the inimitable @AndreaNecchi. He has done a phenomenal job of bringing leaders in GU #oncology from around the world to exchange ideas & develop guidelines.

Join us live !

Out in @ESMO_Open @myESMO an important study led by @BrigidaMaiorano: Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study https://t.co/snTnJW2R2v @UroDocAsh @SpiessPhilippe @montypal @neerajaiims

A network meta-analysis shows that treatment choice in #mHSPC should be guided by disease volume. #ClinicalResearch #Genitourinary #ProstateCancer #Oncology #MetaAnalysis More info here: https://t.co/xYIEMlvTrG

@EAU_YAUProstate is cool! Nice to have meet all in Prague at #EMUC25, beer and brainstorms!

Future is bright for #bladdercancer ! Happy to participate in this interesting session at #EMUC2025

We have almost arrived…1 week left! @SanRaffaeleMI #GURetreat25 @IBCG_BladderCA @GTumors November 21-22 Milan, IT & live stream on YouTube channel @urotoday @OncoAlert @VJOncology @GUOncologyNow @UrologyTimes @Larvol

Could not Miss the challenge of expert session so nicely chaired by our own @BrigidaMaiorano with Charles Nguyen. Second Line therapy of urothelial cancer has become quite complicated! @SanRaffaeleMI @MyUniSR @cityofhope @montypal @neerajaiims @SpiessPhilippe @UroDocAsh

The 2nd International Aron meeting at #ESMO25 A day full of emotions with all of @aron_project friends @myESMO @MatteoSantoniMD @drenriquegrande @fsabino_onco @SoaresAndrey @JaviMolinaC

Neoadjuvant spark by @AndreaNecchi with the GDFather-NEO Ph.II, blinded trial: nivolumab + GDF-15 Ab visugromab vs nivo + placebo. pCR : 33.3% vs 7.1%. MPR 66.7% vs 21.4%. Radiological response: ORR 60.0% vs 14.3%. #ESMO25 #BladderCancer @myESMO @OncoAlert @OncLive

Let’s start #IBCN25! @IBCN1997 @pcvblack @SWilliams_MD @WesKassouf @CMercinelli @mouwlab

⁦@AntureIT⁩ ⁦@MyUniSR⁩ ⁦@SanRaffaeleMI⁩ ⁦@CMercinelli⁩ ⁦@vale_tateo⁩ ⁦@Anto_cigliola⁩ ⁦@BrigidaMaiorano⁩